Earnings Feed
Start Free
Silexion Therapeutics Corp·4

Feb 25, 4:23 PM ET

Noy Shlomo 4

4 · Silexion Therapeutics Corp · Filed Feb 25, 2026

Insider Transaction Report

Form 4
Period: 2026-02-20
Silexion Therapeutics CorpSLXN
Noy Shlomo
Director
Transactions
  • Award

    Ordinary Shares

    [F1][F2]
    2026-02-20+9,091→ 25,399 total(indirect: By Guangzhou Sino-Israel Biotech Fund)
  • Award

    Stock Option (right to buy ordinary shares)

    [F3][F4][F2]
    2026-02-20+10,685→ 10,685 total(indirect: By Guangzhou Sino-Israel Biotech Fund)
    Exercise: $1.65From: 2027-02-12Exp: 2036-02-12→ Ordinary Shares (10,685 underlying)
Holdings

  • Stock Option (right to buy ordinary shares)

    [F5][F2]
    (indirect: By Guangzhou Sino-Israel Biotech Fund)
    Exercise: $18.90From: 2026-02-09Exp: 2035-02-09→ Ordinary Shares (1,872 underlying)
    1,872
Footnotes (5)
  • [F1]The transaction reported in this row consists of the grant to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer. The grant was approved by the Issuer's board of directors.
  • [F2]The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.
  • [F3]The transaction reported in this row consists of the grant to GIBF by the Issuer of options to purchase ordinary shares, for director services provided by Avner Lushi (the Managing Partner and CEO of GIBF) to the Issuer, which grant was approved by the Issuer's board of directors.
  • [F4]The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
  • [F5]There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Signature
/s/ Mirit Horenshtein Hadar, Attorney-in-fact|2026-02-25

Documents

2 files